Sulthiame (Ospolot) is a sulphonamide derivative with carbonic anhydrase inhibiting properties. It has been shown in animals (Wirth et al., 1961) to have anticonvulsant properties, like acetazolamide, but it lacks diuretic effect. It has become popular in Germany and, more recently, in England, for treating all types of major epilepsy. Early studies in patients (LaVeck et al., 1962; Liske and Forster, 1963; Gordon, 1964) showed that it was an effective anticonvulsant when given in combination with other drugs for major epilepsy. It has been used as sole treatment in only small numbers of patients, and has not been tested alone in a placebo-controlled trial.
The incidence of adverse effects has been high in most trials (Gordon, 1964) , and two recent studies have suggested one possible explanation for this. When sulthiame is added to existing phenytoin therapy, the serum level of the latter drug has been shown to rise, often to toxic levels (Olesen and Jensen, 1969) . Inhibition of hepatic metabolism of phenytoin was suggested by the demonstration of an increased serum half-life of the drug (Hansen et al., 1968) . Oleson and Jensen (1969) , however, concluded that phenytoin metabolism was unaffected for they showed no consistent change in the urinary excretion of the major metabolite when sulthiame was added to their patients' treatment. They suggested an alternative explanation, that phenytoin bound to sites such as red cells might be displaced by sulthiame. This interaction between the two drugs has 275 two consequences. First, it may account entirely or in part for the anticonvulsant action of sulthiame and, second, it may lead to intoxication in patients who have been receiving phenytoin without adverse effect for a number of years. Although this latter effect is likely to be important when sulthiame is used, as it often is, as supplementary treatment in patients whose fits have been difficult to control and who are already receiving large doses of anticonvulsant drugs, the frequency with which it occurs in clinical practice has not been adequately assessed. The purpose of this paper is to evaluate the practical importance of this interaction in patients newly admitted for assessment in a Special Centre for Epilepsy, and to report our observations on four long-stay patients with severe epilepsy who were given sulthiame in an attempt to achieve better control of their fits.
METHODS
The National Hospital-Chalfont at approximately 7.00 hours, before the first dose of drugs for that day. Serum phenytoin was estimated in these specimens by gas chromatography using a flash-methylation method which has been described in detail elsewhere (Houghton et al., 1972) . In an inter-laboratory quality control scheme organized by us, this method has given consistent results, although on average about 4-8 ,uM (1-2 ,ug/ml.) higher than the mean of the 20 other participating laboratories.
In our experience few patients with serum phenytoin levels below 100 ,uM (25 ,ug/ml.) show signs of phenytoin intoxication and we therefore regard this level as the upper limit of the therapeutic range. This is higher than the generally accepted upper limit of 80 F±M (20 ,ug/ml.) (Buchthal et al., 1960 were also taking sulthiame. The dose of phenytoin varied from 100 to 500 mg/day, and that of sulthiame from 100 to 800 mg/day. One patient, who had a toxic serum phenytoin level of 115 ,uM (29 ,ug/ml.), was receiving p-aminosalicylic acid and isoniazid for tuberculosis, and was therefore excluded because isoniazid is known to inhibit phenytoin metabolism (Kutt et al., 1966) . It can be seen from Table 1 that 40%o of patients receiving a combination of sulthiame whereas none of the patients on combined treatment was doing so. In order to examine the effect of sulthiame on serum phenytoin in patients on a standard dose of phenytoin, the data have been re-examined in patients receiving 300 mg/day. Table 3 shows the results in the 83 patients included in this group, and Fig. 1 illustrates the distribution of serum phenytoin levels. Again there is a significant difference between the number of patients intoxicated and the mean serum phenytoin levels.
Two patients who were clinically intoxicated on admission and who were on combined treatment were selected for detailed study. The metabolism of phenytoin was examined by estimating the steady state serum phenytoin level, serum half-life, and urinary HPPH:DPH ratio before and after withdrawing sulthiame treatment without any other drug change. The results of these investigations are illustrated in Fig. 2 This patient was a 29 year old female who developed major fits at the age of 12 years. A left sided parietal lesion from birth trauma was suggested by rightsided facial twitching during minor attacks, and by an asymmetrical distribution of spikes and slow waves in the EEG. As well as minor attacks, she had frequent major fits, often several in a short time. She was receiving phenytoin 300 mg/day, primidone 750 mg/day, and diazepam 20 mg/day. Addition of sulthiame appeared to lessen the frequency of her attacks but, by the 32nd day, she was becoming ataxic and had developed nystagmus and hyperventilation. Sulthiame was therefore tailed off. Her serum phenytoin level had risen from 54 ,uM ,ug/ml.) to 90 ,iM (22-5 ,ug/ml.) on the 22nd day. ._ _-----_--_ __ sided twitching occurred in some of the shorter attacks, but EEG recordings had shown only diffuse slow and sharp waves. She had twice been in status epilepticus, when 24 years and 29 years of age. She was receiving phenytoin 300 mg/day, phenobarbitone 150 mg/day, and carbamazepine 600 mg/day. Sulthiame treatment led to a reduction in the frequency and severity of her fits, but by the 32nd day she had become drowsy, muddled, uncooperative, and ataxic, and had developed nystagmus and slurred speech. Sulthiame was therefore tailed off. Her initial serum phenytoin level was 58 ,uM (14-5 ,tg/ml.) but by the 34th day a level of 112 ,iM (28 ,ug/ml.) was recorded.
DISCUSSION
We have confirmed the findings of Hansen et al. (1968) and Olesen and Jensen (1969) that sulthiame causes an elevation of serum levels of phenytoin. In our newly admitted patients this elevation averaged 7400, and was sufficient to produce a risk of phenytoin intoxication three times greater in patients on combined treatment than in those on phenytoin alone. Indeed, 4000 of patients receiving sulthiame were phenytoin intoxicated. It can be argued that the population we have studied is not representative of the epileptic population in general, and that they might be more at risk to drug intoxication. Certainly the patients admitted to the National HospitalChalfont Centre for Epilepsy have problems, often with their fits, but it should be noted that the average phenytoin intake of the 136 patients receiving the drug was 285 mg, which is slightly less than the standard dose in common use. The daily intake was almost identical in the two groups in Table 1 , and differences in phenytoin dose cannot, therefore, account for the higher serum phenytoin level in patients on sulthiame. This becomes even more obvious when analysis is confined to those patients receiving the standard dose of 300 mg/day of phenytoin (Table 3) .
Indeed, the differences between the two groups become even greater. It seems that the dose of phenytoin required to produce intoxication in a group of patients is much less when sulthiame also is present. It can be seen from One of our long-stay patients (R.M.) who was put on sulthiame became clinically severely drug intoxicated despite a minimal increase in serum phenytoin level (Fig. 3) . He was receiving substantial doses of four other drugs-namely, primidone, pheneturide, ethosuximide, and diazepam-and therefore the question arises whether the metabolism of these other drugs might also be inhibited. A slight increase in serum phenobarbitone was shown by Olesen and Jensen (1969) , and therefore it is possible that an increase in serum phenobarbitone (derived from primidone) may have accounted for this patient's symptoms. An alternative explanation of the discrepancy between R.M.'s clinical state and phenytoin level is that sulthiame itself was producing the signs of intoxication. It is not possible to decide which explanation is the correct one until more is known about the effect of sulthiame on the metabolism of other drugs. We are at present investigating this. Two of our four longstay patients developed obvious hyperventilation, and one complained of tenderness over the testicles and vas deferens. We have recently encountered this latter symptom in a normal volunteer taking sulthiame for research purposes, but it has not, to the best ofour knowledge, been reported previously.
The considerable effect that sulthiame has on serum phenytoin levels raises the question of whether sulthiame is an anticonvulsant in its own right, or whether it acts through its interference with phenytoin (and possibly other drug) metabolism. It is not possible to answer this question on the available evidence, but certainly an average increase of 740 % in the serum phenytoin level would be expected to produce a substantial improvement in fit control, regardless of any additional effect of sulthiame itself. Although in some trials it has been given to small numbers of patients as the sole treatment, none of these studies has been performed with a double-blind placebo-controlled design (Green and Kupferberg, 1972) , and therefore it must still be regarded as an open question whether or not sulthiame has anticonvulsant properties of its own in man.
The mechanism of the interaction has been disputed. Hansen et al. (1968) found an increase in the serum half-life of a tracer dose of radioactive phenytoin, and considered that sulthiame, or one of its metabolites, inhibits the hydroxylase enzyme in the liver which is responsible for converting phenytoin to its inactive metabolite, HPPH. On the other hand, Olesen and Jensen (1969) found no consistent change in the 24 hour urinary excretion of HPPH. Our preliminary results in two patients, M.S. and P.H. (Fig. 2) , have confirmed the marked effect of sulthiame on the serum half-life of phenytoin, and in addition have shown that the HPPH: DPH ratio increases that is, changes in favour of the metabolite-when sulthiame treatment is stopped. We consider that this ratio is a more useful measure of phenytoin metabolism than estimating the total daily excretion of HPPH, for the latter varies considerably from day to day and is dependent upon the accuracy with which the patient's urine is collected over 24 hours. A change in the HPPH: DPH ratio reflects a change in the activity of the hepatic hydroxylase enzyme, and thus our evidence supports the view of Hansen et al. (1968) that sulthiame (or one of its metabolites) inhibits this enzyme system. We are investigating this problem further.
